Yahoo Finance

Cordis to Present SELUTION SLR™ Drug-Eluting Balloon Clinical Data at CRT 2026

Presentations Include 12-Month Outcomes from the SELUTION4ISR Trial and the SELUTION DeNovo Trial in Coronary Lesions, Alongside Analyses on How Procedural Experience Influences Treatment Strategy ...
Yahoo Finance

Cordis Launches SELUTION SLR™ PTA Drug-Eluting Balloon (DEB) in Japan

TOKYO, April 28, 2026 /PRNewswire/ -- Cordis, a global leader in interventional cardiovascular technologies, today announces the launch and availability of the SELUTION SLR™ PTA Drug-Eluting Balloon ...
Business Insider

MedAlliance announces Completion of Enrolment in PRISTINE Clinical Trial with SELUTION SLR™ Sirolimus Drug Eluting Balloon

NYON, Switzerland, Aug. 13, 2021 /PRNewswire/ -- MedAlliance has announced completion of patient enrolment in the PRISTINE clinical trial with SELUTION SLR™ 018 DEB (drug-eluting balloon) for the ...
WWLP-22News

MedAlliance's SELUTION SLR drug eluting balloon (DEB) receives FDA investigational device exemption (IDE) approval - making it the first limus DEB to be available to US patients

GENEVA, May 30, 2022 /PRNewswire/ -- The SELUTION SLR (Sustained Limus Release) is a novel sirolimus-eluting balloon that provides a controlled sustained drug release, similar to a drug-eluting stent ...
Yahoo Finance

Cordis Launches SELUTION SLR™ PTA Drug-Eluting Balloon (DEB) in Japan

Cordis, a global leader in interventional cardiovascular technologies, announces the launch and availability of the SELUTION SLR™ PTA Drug-Eluting Balloon for use in Japan. SELUTION SLR™ DEB is ...
Fox2Now St. Louis

MedAlliance's SELUTION SLR drug-eluting balloon (DEB) receives FDA investigational device exemption (IDE) approval, making it the first limus DEB to be available to US patients

GENEVA, May 26, 2022 /PRNewswire/ -- The SELUTION SLR (Sustained Limus Release) is a novel sirolimus-eluting balloon that provides a controlled sustained drug release, similar to a drug-eluting stent ...